Continuous population-level monitoring of SARS-CoV-2 seroprevalence in a large European metropolitan region

Effective public health measures against SARS-CoV-2 require granular knowledge of population-level immune responses. We developed a Tripartite Automated Blood Immunoassay (TRABI) to assess the IgG response against three SARS-CoV-2 proteins. We used TRABI for continuous seromonitoring of hospital pat...

Full description

Saved in:
Bibliographic Details
Published iniScience Vol. 26; no. 2; p. 105928
Main Authors Emmenegger, Marc, De Cecco, Elena, Lamparter, David, Jacquat, Raphaël P.B., Riou, Julien, Menges, Dominik, Ballouz, Tala, Ebner, Daniel, Schneider, Matthias M., Morales, Itzel Condado, Doğançay, Berre, Guo, Jingjing, Wiedmer, Anne, Domange, Julie, Imeri, Marigona, Moos, Rita, Zografou, Chryssa, Batkitar, Leyla, Madrigal, Lidia, Schneider, Dezirae, Trevisan, Chiara, Gonzalez-Guerra, Andres, Carrella, Alessandra, Dubach, Irina L., Xu, Catherine K., Meisl, Georg, Kosmoliaptsis, Vasilis, Malinauskas, Tomas, Burgess-Brown, Nicola, Owens, Ray, Hatch, Stephanie, Mongkolsapaya, Juthathip, Screaton, Gavin R., Schubert, Katharina, Huck, John D., Liu, Feimei, Pojer, Florence, Lau, Kelvin, Hacker, David, Probst-Müller, Elsbeth, Cervia, Carlo, Nilsson, Jakob, Boyman, Onur, Saleh, Lanja, Spanaus, Katharina, von Eckardstein, Arnold, Schaer, Dominik J., Ban, Nenad, Tsai, Ching-Ju, Marino, Jacopo, Schertler, Gebhard F.X., Ebert, Nadine, Thiel, Volker, Gottschalk, Jochen, Frey, Beat M., Reimann, Regina R., Hornemann, Simone, Ring, Aaron M., Knowles, Tuomas P.J., Puhan, Milo A., Althaus, Christian L., Xenarios, Ioannis, Stuart, David I., Aguzzi, Adriano
Format Journal Article
LanguageEnglish
Published United States Elsevier Inc 17.02.2023
The Authors
Elsevier
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:Effective public health measures against SARS-CoV-2 require granular knowledge of population-level immune responses. We developed a Tripartite Automated Blood Immunoassay (TRABI) to assess the IgG response against three SARS-CoV-2 proteins. We used TRABI for continuous seromonitoring of hospital patients and blood donors (n = 72′250) in the canton of Zurich from December 2019 to December 2020 (pre-vaccine period). We found that antibodies waned with a half-life of 75 days, whereas the cumulative incidence rose from 2.3% in June 2020 to 12.2% in mid-December 2020. A follow-up health survey indicated that about 10% of patients infected with wildtype SARS-CoV-2 sustained some symptoms at least twelve months post COVID-19. Crucially, we found no evidence of a difference in long-term complications between those whose infection was symptomatic and those with asymptomatic acute infection. The cohort of asymptomatic SARS-CoV-2-infected subjects represents a resource for the study of chronic and possibly unexpected sequelae. [Display omitted] •We continuously assessed SARS-CoV-2 seroprevalence in two cohorts (n = 72′250).•Modeled cumulative incidence was 3 × higher than suggested by PCR-based testing•On the population level, antibody half-life was 75 days•10% of individuals maintained symptoms one year post–COVID-19 Immunology; Microbiology; Virology; Biological database
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
Equal contribution
Lead contact
ISSN:2589-0042
2589-0042
DOI:10.1016/j.isci.2023.105928